Artemis Institute for Clinical Research Report issue

For profit Phase 2
Founded: San Diego CA United States (2008)

Organization Overview

First Clinical Trial
2010
NCT01189812
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Aretmis Institute for Clinical Research | Artemis Clinical Research | Artemis Clinical Research, San Diego CA | Artemis Institute for Clinical Research

Active Ingredients

Drugs in Phase 2 Trials (3)

citalopram (celexa) (1 trial)

lithium (lithonate) (1 trial)

rapastinel (1 trial)

Drugs in Other Trials (2)

buprenorphine (1 trial)

naloxone (narcan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Borderline Personality Disorder (Phase 2)

Depression (Phase 2)

Depressive Disorder (Phase 2)

Depressive Disorder, Major (Phase 2)

Disease (Phase 2)

Mood Disorders (Phase 2)

Personality Disorders (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 5